Sensei Biotherapeutics (NASDAQ:FTH) Shares Down 6.3% – What’s Next?

Sensei Biotherapeutics, Inc. (NASDAQ:FTH)’s share price traded down 6.3% during trading on Thursday. The stock traded as low as $27.77 and last traded at $27.8650. 161,127 shares traded hands during trading, a decline of 32% from the average daily volume of 238,595 shares. The stock had previously closed at $29.74.

Analyst Ratings Changes

A number of analysts recently issued reports on FTH shares. Cantor Fitzgerald reissued an “overweight” rating on shares of Sensei Biotherapeutics in a research report on Thursday, June 4th. Guggenheim initiated coverage on Sensei Biotherapeutics in a report on Wednesday, September 16th. They issued a “buy” rating and a $70.00 price objective on the stock. Wall Street Zen downgraded shares of Sensei Biotherapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, September 26th. Robert W. Baird assumed coverage on shares of Sensei Biotherapeutics in a report on Friday, June 26th. They set an “outperform” rating and a $57.00 price target on the stock. Finally, TD Cowen assumed coverage on shares of Sensei Biotherapeutics in a research note on Wednesday, September 9th. They issued a “buy” rating for the company. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $56.25.

Sensei Biotherapeutics Price Performance

The firm has a 50 day simple moving average of $32.08. The stock has a market cap of $721.48 million, a price-to-earnings ratio of -0.20 and a beta of -0.28.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its earnings results on Tuesday, August 4th. The company reported ($2.84) EPS for the quarter, topping the consensus estimate of ($5.04) by $2.20. As a group, research analysts expect that Sensei Biotherapeutics, Inc. will post -13.69 EPS for the current fiscal year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Citadel Advisors LLC acquired a new position in shares of Sensei Biotherapeutics during the second quarter valued at about $307,000. Renaissance Technologies LLC grew its holdings in shares of Sensei Biotherapeutics by 178.2% during the 1st quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock worth $1,010,000 after purchasing an additional 20,525 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Sensei Biotherapeutics by 10,692.5% during the 1st quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock worth $1,041,000 after purchasing an additional 32,719 shares in the last quarter. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics during the second quarter valued at approximately $3,610,000. Finally, Stempoint Capital LP acquired a new position in shares of Sensei Biotherapeutics in the first quarter valued at $4,188,000. Institutional investors own 10.50% of the company’s stock.

Sensei Biotherapeutics Company Profile

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on developing immunotherapies for the treatment of cancer. The company’s research is centered on activating and directing the immune system to recognize and attack tumor cells.

Sensei’s technology platform is designed to generate Immune Modulating Antibodies, or IMAs, which are intended to stimulate anti-tumor immune responses by targeting mechanisms involved in immune regulation. Its development programs have included antibody-based therapies evaluated for solid tumors, including programs studied in combination with established checkpoint inhibitors.

The company was founded in 2018 and is based in Cambridge, Massachusetts.